Viatris (VTRS) Goldman Sachs 45th Annual Global Healthcare Conference summary

Strategic transformation and financial priorities

• 2024 is a transition year, completing divestitures and entering phase II of the strategic plan.

• Strong Q1 performance, with $250 million in share buybacks and continued dividend payments.

• Focus on acquiring cornerstone assets with high unmet medical need and long-term revenue potential.

• Strengthened leadership team with new executives and skill sets.

• Deleveraging and sector-leading free cash flow ($2.3–$2.5 billion/year) to support future growth.

Asset acquisition and pipeline strategy

• Eye care division expanding with two marketed products and several late-stage assets.

• Recent acquisitions (cenerimod, selatogrel) targeted as potential blockbuster, differentiated assets.

• Preference for late-stage, de-risked assets (phase III or commercial-ready) to minimize development risk.

• Business development to focus on partnerships, licensing, and disciplined portfolio expansion.

• Ongoing search for near-term revenue opportunities alongside long-term growth assets.

R&D, product launches, and growth outlook

• Annual goal to add $400–$550 million in new product revenue to offset base business erosion.

• Portfolio approach to R&D, including collaborations to share development costs.

• Base business expected to grow 1–3% annually, with new products accelerating overall growth.

• New product launches in North America and globally are stabilizing and growing the business.

• Plan to move from low single-digit to higher growth by layering innovative, durable revenue streams.